REFERENCES
- Bantar C, Bavestrello L, Curcio D et al. Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American Work-ing Group (ConsenSur). J Chemother 2002; 14 (Suppl 4): 1–22.
- Bartlett JG, Dowell SF, Mandell LA et al. Practice guide-lines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347–82.
- Huchon G & European Study on Community-acquired Pneumonia. Guidelines for management of adult community-ac-quired lower respiratory tract infections. Eur Resp J 1998; 11: 986–91.
- Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-ab-dominal infections. Clin Infect Dis 2003; 37: 997–1005.
- Yanagihara K, Fukuda Y, Seki M et al. Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia. Intern Med 2006; 45: 995–9.
- Williams D, Perri M, Zervos MJ. Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the ther-apy of community acquired pneumonia. Eur J Clin Microbiol In-fect Dis 1994; 13: 293–8.
- Rafailidis PI, loannidou EN, Falagas ME. Ampicillin/sul-bactam: current status in severe bacterial infections. Drugs 2007; 67: 1829-49.
- Lister PD, Sanders CC. Comparison of ampicillin-sulbac-tam regimens simulating 1.5- and 3.0-gram doses to humans in treatment of Escherichia coil bacteremia in mice. Antimicrob Agents Chemother 1995; 39: 930–6.
- Alexov M, Lister PD, Sanders CC. Efficacy of ampicillin-sul-bactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions. Antimicrob Agents Chemother 1996; 40: 2468–77.
- Bantar C, Nicola F, Arenoso H et al. Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-b-lactamase inhibitor combination, against Escherichia coil. Antimicrob Agents Chemother 1999; 43: 1503–4.
- Bantar C, Nicola F, Fernandez Canigia L et al. A phar-macodynamic model to support a twelve-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections. J Chemother 2000; 12: 223–27.
- Bantar C, Nicola F, Fernandez Canigia L, et al. Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through a pharmacody-namic analysis in the setting of aminopenicillin-resistant organ-isms. J Chemother 2001; 13: 402–6.
- Bantar C, Nicola F, Arenoso H, Soutric J, Caruso N, Fer-nández Canigia L. An ex-vivo pharmacodynamic study compar-ing bactericidal activity of amoxicillin/sulbactam, azithromycin, doxycycline and levofloxacin against Streptococcus pneumoniae. J Chemother 2004; 16: 248–54.
- Soutric J, Bantar C, Caruso N et al. Review of pharma-cokinetic, pharmacodynamic and clinical studies with a modern combination of amoxicillin/sulbactam. Chemotherapy 2006; 52: 200–4.
- Barcelona L, Marin M, Stamboulian D. Betalactam antibi-otics combined with bectalactamases inhibitors. Amoxicillin-sul-bactam. Medicina (B Aires) 2008; 68: 65–74.
- Carson JG, Turpin RS, Hu H, Ma L, Wilson SE. Cost analysis of five antimicrobial regimens for the treatment of intra-abdominal infection. Surg Infect (Larchmt) 2008; 9: 15–21.
- McKinnon PS, Neuhauser MM. Efficacy and cost of ampi-cillin-sulbactam and ticarcillin-clavulanate in the treatment of hos-pitalized patients with bacterial infections. Pharmacotherapy 1999; 19: 724–33.
- Lodise TP, Lomaestro BM, Drusano GL; Society of Infec-tious Diseases Pharmacists. Application of antimicrobial phar-macodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26: 1320-32.